Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal

Blockhead

22小時前

Avidity Biosciences (RNA) stock rocketed Wednesday on a report Novartis (NVS) made an attempt to buy the rare disease-focused biotech company.

The small biotech company has three drugs in clinical testing that target different forms of muscular dystrophy. In late 2024, Chief Executive Sarah Boyce told Investor's Business Daily that two of those could be "multibillion-dollar drugs."

For Novartis, the potential deal would be one of the biggest under Chief Executive Vas Narasimhan. Avidity's market cap is approaching $6 billion after Financial Times first reported the rumored deal, citing people familiar with the matter.

Representatives of both companies declined to comment in response to inquiries from IBD.

In midday trades, Avidity Biosciences shares surged more than 21% to 46.66.

More to follow.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Amgen Beats Second-Quarter Expectations, So Why Are Shares Diving?

Novo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

Get Timely Buy & Sell Alerts With IBD Leaderboard

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2557309315"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557309315\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2557309315?lang=zh_TW&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg","is_english":true,"pubTime":"2025-08-07 00:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557309315","market":"fut","top_or_hot":-1,"title":"Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal","media":"Blockhead","content":"<html><body><div>\n<p><strong><a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a></strong> (RNA) stock rocketed Wednesday on a report <strong>Novartis</strong> (NVS) made an attempt to buy the rare disease-focused biotech company.</p>\n<p>The small biotech company has three drugs in clinical testing that target different forms of muscular dystrophy. In late 2024, Chief Executive Sarah Boyce told Investor's Business Daily that two of those could be \"multibillion-dollar drugs.\"</p>\n<div>\n<div></div>\n</div>\n<p>For Novartis, the potential deal would be one of the biggest under Chief Executive Vas Narasimhan. Avidity's market cap is approaching $6 billion after Financial Times first reported the rumored deal, citing people familiar with the matter.</p>\n<p>Representatives of both companies declined to comment in response to inquiries from IBD.</p>\n<p>In midday trades, Avidity Biosciences shares surged more than 21% to 46.66.</p>\n<p>More to follow.</p>\n<p><em>Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.</em></p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p>Amgen Beats Second-Quarter Expectations, So Why Are Shares Diving?</p>\n<p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic</p>\n<p>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</p>\n<p>Looking For The Next Apple Or <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>? Start With These S&amp;P 500-Beating Lists</p>\n<p>Get Timely Buy &amp; Sell Alerts With IBD Leaderboard</p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAvidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Blockhead</strong><span class=\"h-time small\">2025-08-07 00:46</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<p><strong><a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a></strong> (RNA) stock rocketed Wednesday on a report <strong>Novartis</strong> (NVS) made an attempt to buy the rare disease-focused biotech company.</p>\n<p>The small biotech company has three drugs in clinical testing that target different forms of muscular dystrophy. In late 2024, Chief Executive Sarah Boyce told Investor's Business Daily that two of those could be \"multibillion-dollar drugs.\"</p>\n<div>\n<div></div>\n</div>\n<p>For Novartis, the potential deal would be one of the biggest under Chief Executive Vas Narasimhan. Avidity's market cap is approaching $6 billion after Financial Times first reported the rumored deal, citing people familiar with the matter.</p>\n<p>Representatives of both companies declined to comment in response to inquiries from IBD.</p>\n<p>In midday trades, Avidity Biosciences shares surged more than 21% to 46.66.</p>\n<p>More to follow.</p>\n<p><em>Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.</em></p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p>Amgen Beats Second-Quarter Expectations, So Why Are Shares Diving?</p>\n<p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic</p>\n<p>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</p>\n<p>Looking For The Next Apple Or <a href=\"https://laohu8.com/S/AMZN\">Amazon</a>? Start With These S&amp;P 500-Beating Lists</p>\n<p>Get Timely Buy &amp; Sell Alerts With IBD Leaderboard</p>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.investors.com/news/technology/avidity-biosciences-novartis-rumored-takeover-deal/\">Blockhead</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0211331839.USD","symbol_name":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.investors.com/news/technology/avidity-biosciences-novartis-rumored-takeover-deal/","article_id":"2557309315","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2022/12/Stock-aviditybiosciences-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557309315","pubTimestamp":1754498760,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4007":"制药","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4139":"生物科技","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","RNA":"Avidity Biosciences, Inc.","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4578":"CAR-T","BK4505":"高瓴资本持仓","NVS":"诺华","BK4588":"碎股","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"据报道诺华正在考虑收购交易，Avidity Biosciences股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1,"RNA":1},"content_text":"Avidity Biosciences (RNA) stock rocketed Wednesday on a report Novartis (NVS) made an attempt to buy the rare disease-focused biotech company.\nThe small biotech company has three drugs in clinical testing that target different forms of muscular dystrophy. In late 2024, Chief Executive Sarah Boyce told Investor's Business Daily that two of those could be \"multibillion-dollar drugs.\"\n\n\n\nFor Novartis, the potential deal would be one of the biggest under Chief Executive Vas Narasimhan. Avidity's market cap is approaching $6 billion after Financial Times first reported the rumored deal, citing people familiar with the matter.\nRepresentatives of both companies declined to comment in response to inquiries from IBD.\nIn midday trades, Avidity Biosciences shares surged more than 21% to 46.66.\nMore to follow.\nFollow Allison Gatlin on X/Twitter at @AGatlin_IBD.\nYOU MAY ALSO LIKE:\nAmgen Beats Second-Quarter Expectations, So Why Are Shares Diving?\nNovo Nordisk Slumps As 'Unlawful' Knockoffs Pressure Wegovy, Ozempic\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks\nLooking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists\nGet Timely Buy & Sell Alerts With IBD Leaderboard","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}